Post-stroke patients could get an important boost from HIIT workoutsStudy participants randomized to HIIT workouts had greater improvements in VO2 peak compared to the group doing medium intensity continuous training workouts. Multiple Sclerosis symptoms: DysarthriaAs the latest installment in this continuing series, pharmacist Nancy Banoub examines a symptom of MS that can cause communication difficulties for patients. Could MRI findings help diagnose and tailor treatment for people with schizophrenia? Team from McGill University pinpoint brain areas where structural abnormalities begin. Blood tests for Alzheimer’s may be coming to your doctor's office. Here's what to know New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported Sunday—but some appear to work far better than others. QUIZ: How much do you know about hydration? Do you know which of your patients need to pay most attention to proper hydration? QUIZ: Test your knowledge of nutrition and the mind The contents of your patients’ diet may be the next frontier in mental health. See how much you know about nutritional psychiatry. McGill-led study uncovers possible drug treatment for anorexia nervosa A ‘controversial’ drug designed to treat dementia is showing promising results as a potential option for eating disorder patients. Migraine prevention should include CGRP-targeting therapies as first-line agents Prior failure of other migraine preventive treatments should not be required before using CGRP-targeting therapies for migraine prevention. QUIZ: How much do you know about transient ischemic attacks? Test your knowledge of the assessment and management of TIAs. ALS drug Albrioza to be voluntarily withdrawn from the market in Canada Phase 3 PHOENIX trial showed no significant benefit from Albrioza (sodium phenylbutyrate/ursodoxicoltaurine) compared to placebo. First Previous 1 2 3 4 5 Next Last